IN8bio, Inc. announced a reverse stock split at a 1-for-30 ratio, effective June 5, 2025. As a result, every 30 shares of common stock will be consolidated into one share, with no change in the par value. Following this adjustment, approximately 3,444,234 shares will be outstanding. The company's stock will trade on a split-adjusted basis on Nasdaq starting June 6, 2025, under the new CUSIP number 45674E208. Fractional shares will not be issued, and cash payments will be made in lieu of them.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.